Drug profile · INN
methylprednisolone sodium succinate
A-METHAPRED
methylprednisolone sodium succinate (A-METHAPRED) is a glucocorticoid receptor agonist. Associated with Amneal Pharma Europe Ltd. Route of administration: injection. Current US regulatory status: approved.
Drug details — methylprednisolone sodium succinate
- US status
- approved
- Class
- —
- Route
- INJECTION
- Patents
- 0
- Programs
- 15
- Data quality
- 0.89
Quick answer
methylprednisolone sodium succinate (A-METHAPRED) is a glucocorticoid receptor agonist. Associated with Amneal Pharma Europe Ltd. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
Glucocorticoid receptor agonist
Primary target: Glucocorticoid receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is methylprednisolone sodium succinate?
methylprednisolone sodium succinate (A-METHAPRED) is a glucocorticoid receptor agonist. Associated with Amneal Pharma Europe Ltd. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for methylprednisolone sodium succinate?
A-METHAPRED is a marketed brand name for methylprednisolone sodium succinate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of methylprednisolone sodium succinate?
methylprednisolone sodium succinate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.